EASD 2020: Empagliflozin Does Not Stimulate Compensatory Appetite Responses in Patients With Type 2 Diabetes and Excess Adiposity
Effects of SGLT2 inhibition on drivers of eating behavior need exploration.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.